Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Muscle May Be Protected From Atrophy By A Natural Hormone
Researchers have found a potential new treatment for the common problem of muscle atrophy. Results of the animal study were presented at The Endocrine Society"s 91st Annual Meeting in Washington, D.C. Don't forget to buy zoloft online no prescription.

QLT Announces 12-month Results From Novartis Sponsored MONT BLANC Study Evaluating Standard-fluence Visudyne(R) Combination Therapy
QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th Congress of the European Society of Ophthalmology in Amsterdam, the Netherlands. MONT BLANC is the European study of the Novartis sponsored SUMMIT clinical trial program which investigates the efficacy and safety of combining Visudyne(R) (Novartis Pharma AG) and Lucentis(R) (Novartis Pharma AG, Genentech Inc.). SUMMIT also includes the DENALI study in the US and Canada and the EVEREST study in Asia. MONT BLANC is a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. The purpose of the study is to evaluate whether Visudyne combined with Lucentis is not inferior to Lucentis monotherapy with respect to the mean change from baseline in visual acuity (VA) and to evaluate the proportion of patients with a treatment-free interval of at least three months duration after Month 2. At the Month 12 examination, mean VA in the Visudyne combination therapy group improved 2.5 letters from baseline compared with a 4.4 letter improvement in the Lucentis monotherapy group. In the combination therapy group, 96% of patients had a three-month treatment-free interval, compared with 92% in the Lucentis monotherapy group.

generic viagra online


News of the day
Gender Difference In Heart Failure
Striking differences in the risk factors for developing heart failure (HF) and patient prognosis exist between men and women. Men and women may also respond differently to treatment, raising concerns about whether current practices provide the best care and reinforcing the urgency for sex-specific clinical trials for HF, according to a review article published in the August 4, 2009, issue of the Journal of the American College of Cardiology.
Diagnostics

Expert Discusses HIV-Related Kidney Disease, Susceptibility Among Blacks

The New York Daily News profiled Paul Klotman, chair of the Samuel F. Bronfman Department of Medicine at Mount Sinai, who is "one of the world"s leading experts on the kidney diseases associated with HIV." In the article, Klotman discussed the clinical details of HIV-associated nephropathy (HIVAN), including treatment, causes and symptoms. According to the Daily News, doctors estimate that two million to four million people of African heritage have HIVAN, including between 4 percent and 12 percent of blacks with HIV in the U.S. The article continues, "In recent years, doctors have made tremendous advances in their understanding of both HIV and its associated kidney disease." Klotman said, "In thinking about a cure, we know now that we have to clean out the brain and the kidney. Those are things we have to know if we can ever achieve a cure for AIDS" (Charles, 7/22). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009